US equities |
INTC $92.07 ▲+0.00% SNDK $1,330.05 ▲+0.00% MU $934.27 ▲+0.00% NVDA $213.66 ▲+0.00% GOOGL $283.82 ▲+0.00% AMZN $243.79 ▲+0.00% AAPL $348.91 ▲+0.00% SKHY $162.09 ▲+0.00%
FinancialContent

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

70.73 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
News headline image
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024 ↗
BBIO stock results show that BridgeBio Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Recap: BridgeBio Pharma Q4 Earnings ↗
 
Via Benzinga
BridgeBio Pharma Inc. (NASDAQ: BBIO) is a Stock Spotlight on 1/9
Via Investor Brand Network
News headline image
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
2 Biotechs That Could Get Bought Out in 2024 ↗
These two biotechs have been frequent visitors to the buyout-rumor mill and for good reason. 
Via The Motley Fool
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
What's Going On With BridgeBio Pharma Stock On Monday? ↗
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
Via Benzinga
News headline image
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? ↗
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range. 
Via Investor's Business Daily
News headline image
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
3 Groundbreaking Biotech Stocks to Invest in Now ↗
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
News headline image
7 Exciting Stocks Poised for Explosive Growth in Key Sectors ↗
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns. 
Via InvestorPlace
News headline image
BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
3 Russell 2000 Stocks That Are About to Get Absolutely Crushed ↗
The Russell 2000 has only begun closing its wide gap with other indices, but investors should be weary of these three stocks to sell. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >